Key facts
- It has raised $560K across 1 recorded rounds; the latest was Seed Round ($559K) in Jan 2026.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Caradon Therapeutics
Funding rounds
1 roundsAbout Caradon Therapeutics
Developer of peptide-based therapeutic drugs intended to create long-acting treatments for cardiometabolic diseases in humans and companion animals. The company offers peptide agonist design, proprietary molecular modification technology, therapeutic candidate development, preclinical validation support, formulation optimization, and translational research initiatives, enabling healthcare providers and patients to access innovative treatments for metabolic and cardiovascular conditions with improved efficacy and duration.
- Sector
- Healthcare
- HQ
- Encinitas, CA, United States
- Founded
- 2023
- Website
- caradon.bio/
- Ownership
- Privately Held (backing)
Caradon Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Caradon Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Caradon Therapeutics in its N-PORT filings yet. We sweep new filings monthly.